Comparative Pharmacology
Head-to-head clinical analysis: DULERA versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DULERA versus RAYOS.
DULERA vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DULERA is a combination of formoterol fumarate, a long-acting beta2-adrenergic agonist (LABA), and mometasone furoate, a corticosteroid. Formoterol acts by relaxing bronchial smooth muscle via beta2-receptor activation. Mometasone furoate reduces inflammation in the lungs by inhibiting inflammatory mediators and suppressing immune responses.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Inhalation: 2 inhalations twice daily (morning and evening). Each inhalation delivers mometasone furoate 100/200 mcg and formoterol fumarate 5 mcg.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Formoterol: terminal half-life 10-14 hours (supports twice-daily dosing); Mometasone: terminal half-life 13.8 hours (range 10-20 hours) after inhalation.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Formoterol: 10-15% renal as unchanged drug and metabolites, remainder hepatically cleared; Mometasone: >99% biliary/fecal as metabolites, <1% renal unchanged.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid/Beta2-Agonist Combination
Corticosteroid